Skip to content

CNS Pharmaceuticals, Inc.: 10-Q filed 2024-08-14

What CNS Pharmaceuticals, Inc. reported in its quarterly report filed 2024-08-14 (fiscal Q2 2024): 29 published measures, 88 facts as tagged in accession 0001683168-24-005711.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-14
Fiscal period
fiscal Q2 2024
Accession
0001683168-24-005711 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNS Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-302,469,269USD
At 2023-12-311,700,853USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-306,762,870USD
At 2023-12-316,132,968USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-4,293,601USD
At 2024-03-31-4,430,527USD
At 2023-12-31-4,432,115USD
At 2023-06-302,454,433USD
At 2023-03-313,491,831USD
At 2022-12-318,132,856USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-301,491,559USD
At 2023-12-31548,721USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-2,530,753USD91
2024-01-01 to 2024-06-30-6,075,501USD182
2024-01-01 to 2024-03-31-3,544,748USD91
2023-04-01 to 2023-06-30-4,021,234USD91
2023-01-01 to 2023-06-30-8,953,181USD181
2023-01-01 to 2023-03-31-4,931,947USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-4,842,450USD182
2023-01-01 to 2023-06-30-8,227,359USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-305,785,288USD182
2023-01-01 to 2023-06-302,451,203USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-75,642,404USD
At 2023-12-31-69,566,903USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-30376,643shares91
2024-01-01 to 2024-06-30275,113shares182
2023-04-01 to 2023-06-3077,547shares91
2023-01-01 to 2023-06-3057,874shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-30376,643shares91
2024-01-01 to 2024-06-30275,113shares182
2023-04-01 to 2023-06-3077,547shares91
2023-01-01 to 2023-06-3057,874shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-6.72USD/shares91
2024-01-01 to 2024-06-30-22.08USD/shares182
2023-04-01 to 2023-06-30-51.86USD/shares91
2023-01-01 to 2023-06-30-154.7USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-6.72USD/shares91
2024-01-01 to 2024-06-30-22.08USD/shares182
2023-04-01 to 2023-06-30-51.86USD/shares91
2023-01-01 to 2023-06-30-154.7USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-303,553USD
At 2023-12-314,933USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-06-30437,278USD182
2023-01-01 to 2023-06-30579,983USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-2,528,135USD91
2024-01-01 to 2024-06-30-6,072,989USD182
2023-04-01 to 2023-06-30-4,025,386USD91
2023-01-01 to 2023-06-30-8,951,897USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-302,145,396USD
At 2023-12-311,591,170USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-306,762,870USD
At 2023-12-316,132,968USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-04-01 to 2024-06-302,528,135USD91
2024-01-01 to 2024-06-306,072,989USD182
2023-04-01 to 2023-06-304,025,386USD91
2023-01-01 to 2023-06-308,951,897USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,116,562USD91
2024-01-01 to 2024-06-303,546,974USD182
2023-04-01 to 2023-06-302,845,553USD91
2023-01-01 to 2023-06-306,413,312USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-301,443,274shares
At 2023-12-31124,306shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-301,491,559USD
At 2023-12-31548,721USD
At 2023-06-304,279,251USD
At 2022-12-3110,055,407USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-3071,347,360USD
At 2023-12-3165,134,664USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-06-30637,087USD
At 2023-12-31839,590USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,411,573USD91
2024-01-01 to 2024-06-302,526,015USD182
2023-04-01 to 2023-06-301,179,833USD91
2023-01-01 to 2023-06-302,538,585USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-06-301,570USD182
2023-01-01 to 2023-06-302,282USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-04-01 to 2024-06-304,463USD91
2024-01-01 to 2024-06-3011,088USD182
2023-04-01 to 2023-06-303,650USD91
2023-01-01 to 2023-06-309,086USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-2,618USD91
2024-01-01 to 2024-06-30-2,512USD182
2023-04-01 to 2023-06-304,152USD91
2023-01-01 to 2023-06-30-1,284USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-06-3011,088USD182
2023-01-01 to 2023-06-309,086USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-01-01 to 2024-06-305,958,270USD182
2023-01-01 to 2023-06-301,969,107USD181

Inspect the source

Entity
CNS Pharmaceuticals, Inc. / CIK 0001729427
Captured
2026-09-21T17:25:19.255Z
SEC response SHA-256
7a9f5b08cc816da4b6e557a5f4afa1e594a6e358cf30f85a8bda749cb62b9f40

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001729427.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))